Hoffmann-La Roche Inc.'s HIVID (zalcitabine), also known as ddC,was approved by the FDA for marketing as a monotherapy treatmentfor adults with advanced HIV disease who either have experienceddisease progression while receiving AZT (zidovudine), or who can'ttolerate AZT.HIVID, approved in more than 40 countries as a stand-alone orcombination therapy, previously was indicated in the U.S. only incombination with Burroughs Wellcome Co.'s AZT in select adultswhose CD4 counts had dropped below 300 per cubic millimeter, DianeDonlon, assistant director, public policy and communications forNutley, N.J.-based Hoffmann-La Roche, told BioWorld. A trial ofadvanced HIV patients whose disease had progressed while takingAZT showed HIVID was as least as efficacious as Bristol-MyersSquibb Co.'s ddI (didanosine) in delaying disease progression anddeath.HIVID works by inhibiting the action of reverse transcriptase, a viralenzyme that is critical in the replication cycle of HIV. When HIVID ispresent in the cell, it binds to reverse transcriptase and prevents thevirus' genetic material from binding to the T cell's genetic code. _Jim Shrine
(c) 1997 American Health Consultants. All rights reserved.